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Introduction 
6-Pyruvoyl-tetrahydropterin synthase (PTPS) is 
the second enzyme involved in the biosynthesis of 
tetrahydrobiopterin (BH4)' , the obligatory cofactor 
for the aromatic amino acid hydroxylases2 as well 
as for all types of nitric oxide synthases3 • Defects 
in the PTPS are the most frequent and heterogen-
eous variants of BH4 deficiency<. Three different 
forms of PTPS deficiency can be distinguished: (i) 
A central or severe type, where patients do not have 
sufficient PTPS activity in the brain and in the liver. 
Patients with this type of defect suffer from neu-
rotransmitter deficiency in the central nervous sys-
tem (CNS) and elevated phenylalanine concent-
rations in blood and tissue. They need to be treated 
with BH4, L-Dopa, Carbidopa and 5-hydroxytryp-
tophan to prevent irreversible brain damage. (ii) In 
the partial or peripheral type, patients do not have 
enough PTPS in the liver, but neurotransmitter 
biosynthesis in the brain is normal. They have to 
be treated with BH4 monotherapy or follow a phen-
ylalanine low diet l. (iii) A transient form , where 
patients present clinical symptoms only in the neo-
natal period, has been described in a few cases". 
Since the human liver cDNA was isolated?, it was 
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possible to investigate the cDNA in primary skin 
fibroblasts from PTPS deficient patients in orde r to 
find out the mutations causing the disease. 
In this work three new mutations, a missense 
mutation and two deletions, in two patients suffer-
ing from the severe type of PTPS deficiency are 
described. Furthermore, a summary of all mutations 
found so far in the eDNA of PTPS deficient patients 
and of the clinical data of these patients is given. 
We hope that it will become possible to differentiate 
between variants of PTPS deficiency by finding and 
characterizing the mutations. 
Materials and Methods 
Pterins in urine were measured by HPLC, a fter 
oxidation with manganese dioxide, as described 
previously8. 
The PTPS assay is based on the measurement of 
BH. derived from dihydroneopterin triphosphate 
(substrate) (110 flM) in the presence of NADPH (1 
mM), NADH (l mM), DHPR (220 mU), magnesium 
(10 mM), sepiapterin reductase (5 mU), and Tris-
HCl buffer, pH 7.4 (0.1 M)9. Erythrocytes (50 fll) 
were suspended in 50 fll of 0.2 M Tris-HCl buffer, 
pH 7.4 and lysed by freezing and thawing. The sam-
ple was saturated with carbon monoxide for 1-2 
min unde r slight shaking and 50 fll of the lysate 
were used for the a ssay. The biopterin was measured 
fluorom etrically by HPLC after oxidation with 
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manganese dioxide at pH 1.0-1.5. 
Primary skin fibroblasts were cultured in Dul-
becco's Modified Eagle Medium (Gibco) containing 
10% fetal calf serum (Gibco) and 50 units of peni-
cillin plus 50 /lg/ml streptomycin. Fibroblast lysate 
preparations and PTPS acivity measurements of 
these extracts were performed as described else-
where lO• - , 
Total RNA was isolated from confluent fibroblast 
cultures following a protocol using guanidinium-
thiocyamate for cell lysis and subsequent centrifu-
gation in cesium chloride solution II. With oligo-
deoxythymidine as a primer cDNA was synthesized 
from this total RNAIO• cDNA was PCR-amplified 
and directly sequenced using the dideoxynucleotide 
chain termination method (USB sequencing kit, 
version 2.0) according to Thony et allO • 
Case Reports 
The history of the patients JRS and UT has been 
reported elsewhere l? 
LL is the first child of healthy, non related pa-
rents. On the 5th day the Guthrie test was slightly 
elevated, and the controls on day 10 and 42 were, 
for plasma phenylalanine, in the high normal range. 
His early development was normal. At the age of 
4.5 months he developed a tendency to opistotonus 
progressing later into frequent attacks of hyperto-
nicity of the extremities. The serum phenylalanine 
rose to 2840 flmol/ l , and the BH4 loading test, as 
well as the pattern of urinary pterins confirmed the 
diagnosis of a defective BH" biosynthesis. The child 
was treated with a combination of BH., L-Dopa/ 
Carbidopa, and 5-hydroxytryptophan12• 
SS was diagnosed as hyperphenylalaninemic at 
the age of four days. Plasma phenylalanine ranged 
between 1220 and 2400 /lmol/1. At the age of 5 weeks 
the diagnostic test for BH4 deficiency was perfor-
med; the BH. loading test was positive, neopterin 
was increased, and biopterin was very low. Reduced 
PTPS activity in the patient's erythrocytes confir-
med the diagnosis. SS has been on BH. and neu-
rotransmitter therapy since the age of ten weeks. At 
the age of 12 years her intelligence quotient was 5413. 
Results and Discussion 
Table 1 shows four PTPS deficient patients stu-
died by our group (JRS, UT, LL and SS) with re-
duced PTPS activity in fibroblasts and erythrocytes. 
Three other patients described by Shintaku l '. IS and 
Imamura et al. ls were all of the central type with 
reduced or absent activity of PTPS in the erythro-
cytes. In one patient with the central type of PTPS 
deficiency, described by Ashida et a1. 16 , the activity 
of the enzyme in fibroblasts and erythrocytes was 
20-fold and 5-fold lower, respectively, than that of 
the controls. Serum phenylalanine concentrations 
were elevated in all PTPS deficient patients and in 
Table 1. Summary of information from patients with PTPS deficiency. 
Patient Urinary pterins Serum Phe PTPS activity Mutation Alteration 
(phenotype) (mmol/mol creat) (/lmol/l) Erythrocytes Fibroblasts on on 
Neo Bio %Bio* (/lU/g Hb) (/lU/ mg prot.) DNA level protein level 
JRS 6.5 0.63 9.0 360 1.5 0.03 C ss to T Rl6C 
(peripheral) ~G370-G3.3 Kl20 ---+ stop 
lIT 9.1 0.19 2.1 1200 0 :5:0.02 G 83 to A R25Q 
(central) 
LL 34.3 0.41 1.2 IS00 1.3 :5:0.02 ~G178-GI80 ~V57 
(central) ~T173 -G I 9S K54 ---+ stop 
SS 30.3 0.13 0.4 1220 0.5 :5:0.02 C269 to T PS7L 
(central) 
KH** 15.6 0.04 < 0.1 970 0.1 C 268 to T PS7S 
(central) 
KY** 10.4 0.D7 0.7 1550 0 C 268 to T PS7S 
(central) 
YI** 4O.S 0.12 0.3 6S0 1.0 C 268 to T P87S 
(central) C 295 to A D96N 
XY*** 5.7# 2840 0.43 A 3• 9 to G Ill4V 
(central) 
Controls 1.1-4.0 0.5-0.3 18-63 < 120 11-29 1.9-2.6 none none 
lINeo/Bio 
* %Bio= 100*Bio/ (Neo+ Bio) 
** Ref. 14,15 
*** Ref. 16 
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I1l4V I 100 bp 
5' 3' 
j 
R25Q t> V57 D96N K120 -Stop 
Figure L Human cDNA sequence encoding PTPS, and lo-
cations of mutations in patients with PTPS deficiency. 
all cases initially low biopterin and high neopterin 
levels were detected. 
Five patients were found to be homozygous for 
the mutations R25Q, P87L. 11 14V, and two patients 
showed the same mutation P87S (Figure 1). The 
other three patients harbor the compound hetero-
zygote mutations R16C/K120 ~ stop, a V57 /K54 ~ 
stop and P87S/D96N. All mutations found in the 
cDNA of PTPS deficient patients are in highly 
conserved regions. The codon at position 87 sems 
to be a hot spot for mutations in the 435bp reading 
frame of the PTPS cDNA. Four of eight analyzed 
patients showed a mutation at this position. 
PTPS deficient patients with loower PTPS acti-
vities in erythrocytes and in fibroblasts showed also 
higher serum phenylalanine levels, higher neopterin 
and lower biopterin levels. Data presented in Table 
I and those from previous studies l ? suggested that 
patients with the peripheral type of PTPS deficiency 
presented intermediate biochemical abnormalities. 
Biochemical characterization including kinetic and 
crosslinking experiments will reveal structural and 
functional differences between mutant proteins and 
the wild type PTPS. There was so far no correlation 
between the phenotype and genotype. 
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